GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business
Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.